These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 33501503)

  • 1. Cytokeratin 19 fragment is associated with severity and poor prognosis of interstitial lung disease in anti-MDA5 antibody-positive dermatomyositis.
    Gui X; Ma M; Ding J; Shi S; Xin X; Qiu X; Zhang Y; Qiu Y; Cao M; Huang M; Cao M; Dai J; Cai H; Xiao Y
    Rheumatology (Oxford); 2021 Aug; 60(8):3913-3922. PubMed ID: 33501503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD.
    Horiike Y; Suzuki Y; Fujisawa T; Yasui H; Karayama M; Hozumi H; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Ogawa N; Suda T
    Rheumatology (Oxford); 2019 Dec; 58(12):2143-2152. PubMed ID: 31143953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors of interstitial lung diseases in clinically amyopathic dermatomyositis.
    Gan YZ; Zhang LH; Ma L; Sun F; Li YH; An Y; Li ZG; Ye H
    Chin Med J (Engl); 2020 Mar; 133(6):644-649. PubMed ID: 32049748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.
    Fujisawa T; Hozumi H; Yasui H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Suda T
    J Rheumatol; 2019 Aug; 46(8):935-942. PubMed ID: 31092718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics and prognostic implications of peripheral blood lymphocyte subsets in patients with anti-MDA5 antibody positive dermatomyositis-interstitial lung disease.
    Ren FP; Chen Q; Yao SS; Feng L; Xue XY; Zhao WC; Wang D; Zhao ZL; Gu SW; Li T; Shen YW; Gao L; Zang XL; Bao XY; Tong ZH
    BMC Pulm Med; 2023 Oct; 23(1):411. PubMed ID: 37898737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
    Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
    Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis.
    Gono T; Kawaguchi Y; Satoh T; Kuwana M; Katsumata Y; Takagi K; Masuda I; Tochimoto A; Baba S; Okamoto Y; Ota Y; Yamanaka H
    Rheumatology (Oxford); 2010 Sep; 49(9):1713-9. PubMed ID: 20498012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of radiological patterns of HRCT and their association with macrophage activation in dermatomyositis.
    Zuo Y; Ye L; Liu M; Li S; Liu W; Chen F; Lu X; Gordon P; Wang G; Shu X
    Rheumatology (Oxford); 2020 Oct; 59(10):2829-2837. PubMed ID: 32065646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis.
    Sakamoto S; Okamoto M; Kaieda S; Fujimoto K; Nagata S; Tominaga M; Nakamura M; Zaizen Y; Nouno T; Koga T; Kawayama T; Kuwana M; Ida H; Hoshino T
    Respir Investig; 2018 Nov; 56(6):464-472. PubMed ID: 30150008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction model for the pretreatment evaluation of mortality risk in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with interstitial lung disease.
    Gui X; Li W; Yu Y; Zhao T; Jin Z; Meng K; Wang R; Shi S; Yu M; Ma M; Chen L; Luan W; Xin X; Qiu Y; Qiu X; Zhang Y; Cao M; Cao M; Dai J; Cai H; Huang M; Xiao Y
    Front Immunol; 2022; 13():978708. PubMed ID: 36211445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-MDA5 antibody is associated with A/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis.
    Chen F; Wang D; Shu X; Nakashima R; Wang G
    Rheumatol Int; 2012 Dec; 32(12):3909-15. PubMed ID: 22198664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease.
    Motegi SI; Sekiguchi A; Toki S; Kishi C; Endo Y; Yasuda M; Ikeuchi H; Sakairi T; Hara K; Yamaguchi K; Maeno T; Hiromura K; Ishikawa O
    Eur J Dermatol; 2019 Oct; 29(5):511-517. PubMed ID: 31617496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic evaluation of serum osteopontin in patients with anti-MDA5 antibody-positive dermatomyositis associated interstitial lung disease.
    Gao Y; Zhao Q; Xie M; Yan X; Li Y; Zhang X; Wu H; Dai J; Cao M; Cai H
    Cytokine; 2020 Nov; 135():155209. PubMed ID: 32738770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Role of Interferon-λ3 in Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis-Associated Interstitial Lung Disease.
    Fukada A; Fujisawa T; Hozumi H; Koda K; Akamatsu T; Oyama Y; Satake Y; Niwa M; Kaida Y; Matsuda H; Yokomura K; Koshimizu N; Toyoshima M; Imokawa S; Hashimoto D; Yoshida A; Gono T; Kuwana M; Yamano Y; Kondoh Y; Yamashita K; Maekawa M; Mori K; Inoue Y; Yasui H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Inui N; Suda T
    Arthritis Rheumatol; 2024 May; 76(5):796-805. PubMed ID: 38146102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease.
    Ye Y; Fu Q; Wang R; Guo Q; Bao C
    J Clin Lab Anal; 2019 Oct; 33(8):e22978. PubMed ID: 31301087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease.
    Xu A; Ye Y; Fu Q; Lian X; Chen S; Guo Q; Lu LJ; Dai M; Lv X; Bao C
    Rheumatology (Oxford); 2021 Jul; 60(7):3343-3351. PubMed ID: 33331866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different Multivariable Risk Factors for Rapid Progressive Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis and Anti-Synthetase Syndrome.
    Zuo Y; Ye L; Chen F; Shen Y; Lu X; Wang G; Shu X
    Front Immunol; 2022; 13():845988. PubMed ID: 35320936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review.
    Huang K; Vinik O; Shojania K; Yeung J; Shupak R; Nimmo M; Avina-Zubieta JA
    Rheumatol Int; 2019 Nov; 39(11):1971-1981. PubMed ID: 31375890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutrophil extracellular traps may contribute to interstitial lung disease associated with anti-MDA5 autoantibody positive dermatomyositis.
    Peng Y; Zhang S; Zhao Y; Liu Y; Yan B
    Clin Rheumatol; 2018 Jan; 37(1):107-115. PubMed ID: 28842784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum YKL-40 level is associated with severity of interstitial lung disease and poor prognosis in dermatomyositis with anti-MDA5 antibody.
    Jiang L; Wang Y; Peng Q; Shu X; Wang G; Wu X
    Clin Rheumatol; 2019 Jun; 38(6):1655-1663. PubMed ID: 30739212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.